Parkinson's disease
Neurology · 2008–2025
26decisions
16medicines
7carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| apomorphine hydrochloride hemihydrate Treatment of Parkinson disease with severely disabling motor fluctuations refractory to conventional therapy. Maintenance therapy in patients previously… | Jul 2025 | Recommended | input received |
| levodopa with carbidopa monohydrate and entacapone Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Jul 2024 | Recommended | 2 individuals |
| foslevodopa/foscarbidopa Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | May 2024 | Not recommended | input received Hospital Research Foundation Group |
| levodopa with carbidopa and entacapone Advanced idiopathic Parkinson disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Mar 2024 | Not recommended | 1 individuals |
| foslevodopa with foscarbidopa Treatment of advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | Nov 2024 | Recommended with restriction | 3 individuals |
| levodopa with carbidopa and entacapone Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised alternative pharmacological treatment. | Nov 2024 | Recommended | 2 individuals |
| opicapone Adjunctive therapy to levodopa-decarboxylase inhibitor combination in adult patients with Parkinson disease experiencing end-of-dose motor fluctuations. | Jul 2021 | Recommended with restriction | input received |
| apomorphine Maintenance treatment of Parkinson's disease in patients with severely disabling motor fluctuations not adequately controlled by other therapy, following… | Mar 2020 | Recommended with restriction | none received |
| apomorphine Extension of listing for maintenance treatment of Parkinson's disease following initiation in a hospital setting. | Nov 2020 | Recommended with restriction | none received |
| levodopa with carbidopa monohydrate Advanced Parkinson's disease with severe motor fluctuations not adequately controlled by oral therapy. | Nov 2019 | Recommended with restriction | none received |
| apomorphine hydrochloride hemihydrate Treatment of Parkinson's disease in patients with severely disabling motor fluctuations that have not responded to other therapy. | Jul 2018 | Recommended with restriction | none received |
| apomorphine hydrochloride Treatment of Parkinson's disease in patients with severely disabling motor fluctuations which have not responded to other therapy. | Mar 2018 | Recommended with restriction | unclear |
| safinamide Treatment of Parkinson's disease as add-on therapy to levodopa in patients experiencing motor fluctuations. | Nov 2018 | Recommended with restriction | none received |
| apomorphine To reduce the number and severity of 'off' phases in patients with Parkinson's disease severely disabled by motor fluctuations refractory to conventional… | Jul 2016 | Recommended | no section in document |
| apomorphine Treatment of Parkinson disease in patients with severely disabling motor fluctuations that have not responded to other therapy. | Nov 2016 | Recommended | none received |
| levodopa with carbidopa Advanced Parkinson disease with severe disabling motor fluctuations not adequately controlled by oral therapy. | Nov 2016 | Recommended with restriction | none received |
| apomorphine hydrochloride Management of advanced Parkinson disease in patients with severely disabling motor fluctuations that have not responded to other therapy. | Nov 2014 | Recommended with restriction | no section in document |
| rasagiline Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor… | Mar 2012 | Recommended with restriction | unclear |
| rasagiline Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor… | Mar 2012 | Recommended with restriction | unclear |
| rasagiline Parkinson disease as adjunctive therapy in patients being treated with levodopa-decarboxylase inhibitor combinations who are experiencing fluctuations in motor… | Jul 2011 | Recommended | unclear |
| levodopa with carbidopa (as monohydrate), intestinal gel Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy. Treatment must be… | Nov 2010 | Recommended with restriction | no section in document |
| pramipexole hydrochloride Monotherapy for idiopathic Parkinson disease in patients with motor disability and no evidence of cognitive impairment. | Jul 2009 | Recommended with restriction | no section in document |
| levodopa with carbidopa monohydrate, intestinal gel Initial and continuing treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised oral treatment, administered via… | Mar 2009 | Not recommended | no section in document |
| pramipexole hydrochloride Treatment of signs and symptoms of idiopathic Parkinson disease as monotherapy in early disease or in combination with levodopa in advanced disease. | Jul 2008 | Recommended | no section in document |
| levodopa with carbidopa Advanced idiopathic Parkinson's disease with severe motor fluctuations despite optimised oral treatment, for patients with severe disabling motor fluctuations… | Mar 2008 | Not recommended | no section in document |
| rotigotine Treatment of idiopathic Parkinson's disease from early stage to advanced disease, as monotherapy or in combination with levodopa. | Mar 2008 | Recommended | no section in document |
Who spoke
Hospital Research Foundation Group
What the PBS pays
$516M in government benefit over 2024–25, across 5,090,343 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| levodopa with carbidopa and entacapone | $93.2M |
| levodopa with carbidopa monohydrate and entacapone | $93.2M |
| levodopa with carbidopa | $92.4M |
| levodopa with carbidopa monohydrate | $92.4M |
| levodopa with carbidopa monohydrate, intestinal gel | $92.4M |
| pramipexole hydrochloride | $14.4M |
| apomorphine | $10.9M |
| apomorphine hydrochloride | $10.9M |
| safinamide | $5.5M |
| rotigotine | $5.2M |
| opicapone | $3.2M |
| rasagiline | $2.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| foslevodopa foscarbidopaFoslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | recommended restricted | 2023-11 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| amantadineAMANTADINE MEDICIANZ amantadine hydrochloride 100 mg capsule blister p | 1991 | 4 |
| trihexyphenidylARTANE 2mg trihexyphenidyl (benzhexol) hydrochloride 2mg tablet bottle | 1991 | 2 |
| selegilineELDEPRYL selegiline hydrochloride 5 mg tablet | 1994 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 7 of 17 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.